PROSENSA TECHNOLOGIES BV has a total of 62 patent applications. Its first patent ever was published in 2007. It filed its patents most often in WIPO (World Intellectual Property Organization), China and United States. Its main competitors in its focus markets pharmaceuticals, biotechnology and environmental technology are ARTECEL INC, AVI BIOPHARMA INC and SANBIO INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 11 | |
#2 | China | 10 | |
#3 | United States | 8 | |
#4 | Canada | 7 | |
#5 | EPO (European Patent Office) | 7 | |
#6 | New Zealand | 7 | |
#7 | Israel | 5 | |
#8 | Hong Kong | 4 | |
#9 | Japan | 2 | |
#10 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Environmental technology | |
#4 | Foods and drinks |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Microorganisms | |
#4 | Peptides | |
#5 | Climate change adaptation technologies | |
#6 | Measuring microorganism processes | |
#7 | Enzymes |
# | Name | Total Patents |
---|---|---|
#1 | Van Deutekom Judith Christina Theodora | 23 |
#2 | Platenburg Gerard Johannes | 20 |
#3 | De Kimpe Josephus Johannes | 20 |
#4 | De Visser Peter Christian | 18 |
#5 | Platenburg Gerardus Johannes | 14 |
#6 | Aartsma-Rus Annemieke | 13 |
#7 | Van Ommen Garrit-Jan Boudewijn | 12 |
#8 | Mulders Susan Allegonda Maria | 8 |
#9 | Van Kuik-Romeijn Petra | 7 |
#10 | Van Deutekom Judith Christina | 5 |
Publication | Filing date | Title |
---|---|---|
CA2862628A1 | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy | |
WO2012144906A1 | New compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (dm1) | |
NZ595955A | Oligonucleotide comprising an inosine for treating dmd | |
WO2009139635A1 | Polymyxin derivatives and uses thereof | |
NZ582522A | A conjugate comprsing the amino acid sequence LPWKPLG for targeting compounds to brain cells, neuronal cells or tumour cells of neuronal or neuroectodermal origin | |
EP2167135A2 | Molecules for targeting compounds to various selected organs, tissues or tumor cells | |
EP2119783A1 | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means | |
EP2049664A1 | Single stranded oligonucleotides complementary to repetitive elements for treating DNA repeat instability associated genetic disorders | |
CN101501193A | Methods and means for treating DNA repeat instability associated genetic disorders | |
CN101511430A | Antibiotic composition |